Arcadia Biosciences, Inc.
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 04 Sep 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 10 Aug 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Change of auditor (8-K Item 4.01)
The company reported a change of its independent auditor in a Form 8-K (Item 4.01) filed on 03 Apr 2026. Auditor changes are often routine (rotation, cost, mergers), but can follow disagreements over accounting.
More details →Arcadia Biosciences, Inc. — Overview & Financial Snapshot
Arcadia Biosciences, Inc. (NasdaqCM: RKDA) is a Consumer Defensive company, ranked #1,907 of 6,774 companies globally and #494 of 4,000 in United States on PositoAI, with a Positivity Score of 22,140. Its market capitalisation is ₹3.68 Cr ($389,810), P/E ratio is -0.0 and P/B ratio is 0.62. It currently has 2 active red flags (PosiRed) and 1 yellow flag (PosiYellow, 2/10 points) on record.
For financial statements, ratio trends and score history, Go Deep →